Dexamethasone eyedrop
PreclinicalSmall molecule
Dexamethasone eyedrop is one of 9 small molecule programs targeting Retinopathy of Prematurity. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Retinopathy of Prematurity
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Ketalar
AAultman Health Foundation
Approved
Decadron
AAspen Global Incorporated
Approved
Inderal
WWyeth-Lederle Vaccines
Phase 3
Paracetamol
GSKPreclinical
Feosol
AAuerbach Hematology Oncology Associates P C
Preclinical
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Preclinical
Dexamethasone eyedrop
RRegion Skane
Preclinical
Intravitreal Injection of Ranibizumab
UUniversity of Sao Paulo
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexamethasone eyedrop. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRegion Skane